20. Koyama K, Kagamu H, Miura S, et al.Reciprocal CD4+ T-cell balance of effector CD62low CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.Clin Cancer Res, 2008, 14:6770-6779.
23. Zhao L, Yang J, Wang HP, et al.Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma.Med Oncol, 2013, 30:461.
[4]
24. Brussino L, Culla B, Bucca C, et al.Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.J Breath Res, 2014, 8:27110.
[5]
25. Numasaki M, Lotze MT, Sasaki H.Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts.Immuno Lett, 2004, 93:39-43.
[6]
26. Li Y, Cao ZY, Sun B, et al.Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther, 2011, 12:610-616.
[7]
27. Honorati MC, Neri S, Cattini L, et al.Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts.Osteoarthritis Cartilage, 2006, 14:345-352.
[8]
28. Kuang DM, Zhao Q, Wu Y, et al.Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma.J Hepatol, 2011, 54:948-955.
[9]
29. Pickens SR, Volin MV, Mandelin AN, et al.IL-17 contributes to angiogenesis in rheumatoid arthritis.J Immunol, 2010, 184:3233-3241.
[10]
30. Yang CL, Liu YY, Ma YG, et al.Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.PLoS One, 2012, 7:e37960.
[11]
31. Atsumi T, Singh R, Sabharwal L, et al.Inflammation amplifier, a new paradigm in cancer biology.Cancer Res, 2014, 74:8-14.
[12]
35. Starnes T, Robertson M J, Sledge G, et al.Cutting edge:IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production.J Immunol, 2001, 167:4137-4140.
[13]
37. Lim C, Savan R.The role of the IL-22/IL-22R1 axis in cancer.Cytokine Growth Factor Rev, 2014, 25:257-271.
[14]
40. Yao JS, Zhai W, Young WL, et al.Interleukin-6 triggers human cerebral endothelial cells proliferation and migration:the role for KDR and MMP-9.Biochem Biophys Res Commun, 2006, 342:1396-1404.
[15]
41. Guo Y, Xu F, Lu T, et al.Interleukin-6 signaling pathway in targeted therapy for cancer.Cancer Treat Rev, 2012, 38:904-910.
[16]
1. Hemdan NY.Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells.Immunol Lett, 2013, 149:123-133.
[17]
2. Murugaiyan G, Saha B.Protumor vs antitumor functions of IL-17.J Immunol, 2009, 183:4169-4175.
[18]
3. O'Connor SJ.Review of the incidence, prevalence, mortality and causative factors for lung cancer in Europe.Eur J Cancer, 2011, 47, Supplement 3:S346-S347.
5. Tartour E, Pere H, Maillere B, et al.Angiogenesis and immunity:a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Cancer Metastasis Rev, 2011, 30:83-95.
[21]
6. Horn L, Sandler AB.Angiogenesis in the treatment of non-small cell lung cancer.Proc Am Thorac Soc, 2009, 6:206-217.
[22]
7. Wilke C, Zou W.TH17 cells in the tumor micro-environment.in:TH17 Cells in Health and Disease.New York:Springer Press, 2011, 481-496.
[23]
8. Kim JS, Jordan MS.Diversity of IL-17-producing T lymphocytes.Cell Mol Life Sci, 2013, 70:2271-2290.
[24]
10. Zhang GQ, Han F, Fang XZ, et al.CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis.Asian Pac J Cancer Prev, 2012, 13:3955-3960.
[25]
11. Gaffen SL.An overview of IL-17 function and signaling.Cytokine, 2008, 43:402-407.
[26]
12. Wilke CM, Kryczek I, Wei S, et al.Th17 cells in cancer:help or hindrance? Carcinogenesis, 2011, 32:643-649.
[27]
13. Hus I, Maciag E, Roliński J.The role of Th17 cells in anti-cancer immunity.Postepy Hig Med Dosw(Online), 2010, 64:244-250.
[28]
14. Neurath MF, Finotto S.The emerging role of T cell cytokines in non-small cell lung cancer.Cytokine Growth Factor Rev, 2012, 23:315-322.
[29]
15. Chang SH, Mirabolfathinejad SG, Katta H, et al.T helper 17 cells play a critical pathogenic role in lung cancer.Proc Natl Acad Sci U S A, 2014, 111:5664-5669.
[30]
16. Castermans K, Tabruyn SP, Zeng R, et al.Angiostatic activity of the antitumor cytokine interleukin-21.Blood, 2008, 112:4940-4947.
[31]
17. Ramesh R, Mhashilkar AM, Tanaka F, et al.Melanoma differentiation-associated gene 7/Interleukin(IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.Cancer Res, 2003, 63:5105-5113.
[32]
18. Numasaki M, Fukushi J, Ono M, et al.Interleukin-17 promotes angiogenesis and tumor growth.Blood, 2003, 101:2620-2627.
[33]
44. Sun L, Zhang S, Jiang Z, et al.Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-α-treated A549 cells.Biochem Biophys Res Commun, 2011, 416:99-105.
[34]
46. Baird A, Dockry é, Daly A, et al.IL-23R is epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.Front Oncol, 2013, 3:162.
[35]
9. Kryczek I, Banerjee M, Cheng P, et al.Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.Blood, 2009, 114:1141-1149.
[36]
19. Dimova I, Popivanov G, Djonov V.Angiogenesis in cancer-general pathways and their therapeutic implications.J BUON, 2014, 19:15-21.
[37]
22. Shi W, Li X, Cha Z, et al.Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer.DNA Cell Biol, 2014, 33:355-360.
[38]
32. Tecchio C, Cassatella MA.Neutrophil-derived cytokines involved in physiological and pathological angiogenesis.Chem Immunol Allergy, 2014, 99:123-137.
[39]
33. Numasaki M, Watanabe M, Suzuki T, et al.IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.J Immunol, 2005, 175:6177-6189.
[40]
34. Hymowitz SG, Filvaroff EH, Yin JP, et al.IL-17s adopt a cystine knot fold:structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.EMBO J, 2001, 20:5332-5341.
[41]
36. Xie Y, Sheng W, Xiang J, et al.Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis.Cancer Invest, 2010, 28:598-607.
[42]
38. Weber GF, Gaertner FC, Erl W, et al.IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase.J Immunol, 2006, 177:8266-8272.
[43]
39. Loeffler S, Fayard B, Weis J, et al.Interleukin-6 induces transcriptional activation of vascular endothelial growth factor(VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.Int J Cancer, 2005, 115:202-213.
[44]
42. Kume T.Ligand-dependent Notch signaling in vascular formation.Adv Exp Med Biol, 2012, 727:210-222.
[45]
43. Wu Y, Zhou BP.TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion.Br J Cancer, 2010, 102:639-644.
[46]
45. Liu L, Ge D, Ma L, et al.Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.J Thorac Oncol, 2012, 7:1091-1100.
